Cargando…
Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
Autores principales: | Wright, Jordan J., Salem, Joe-Elie, Johnson, Douglas B., Lebrun-Vignes, Bénédicte, Stamatouli, Angeliki, Thomas, James W., Herold, Kevan C., Moslehi, Javid, Powers, Alvin C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301161/ https://www.ncbi.nlm.nih.gov/pubmed/30305348 http://dx.doi.org/10.2337/dc18-1465 |
Ejemplares similares
-
Hematologic Complications of Immune Checkpoint Inhibitors
por: Davis, Elizabeth J., et al.
Publicado: (2019) -
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
por: Johnson, Douglas B., et al.
Publicado: (2019) -
Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions
por: Moslehi, Javid, et al.
Publicado: (2022) -
Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review
por: Nguyen, Lee S., et al.
Publicado: (2021) -
Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study
por: Hilmi, Marc, et al.
Publicado: (2020)